Purpose Of Review: Since 2008, beta-blockers have become first-line treatment for infantile hemangiomas, the most common tumor of infancy. Their role is also being explored in the treatment of other childhood vascular tumors.
Recent Findings: Recent research has demonstrated that propranolol is a more effective and safer treatment for infantile hemangiomas than previous therapeutic options. It is most effective when initiated during the tumor's proliferative phase. Other oral beta-blockers such as atenolol and nadolol are less studied, but may offer similar efficacy. Topical beta-blockers such as timolol appear to be effective in treating small, superficial infantile hemangiomas. Beta-blockers have shown variable results for the treatment of other vascular tumors of childhood, such as pyogenic granulomas, kaposiform hemangioendotheliomas, and tufted angiomas.
Summary: Propranolol has revolutionized the treatment of infantile hemangiomas, and other beta-blockers provide promising alternatives. Unanswered questions remain about the optimal choice of agent, delivery mechanism, dosage, need for pretreatment evaluation or ongoing monitoring, and duration of therapy. The role of beta-blockers in treating other types of vascular tumors requires further study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MOP.0000000000000238 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The timing and safety of topical timolol treatment for superficial infantile hemangioma: a retrospective cohort study.
Eur J Pediatr
January 2025
Department of Pediatric Surgery, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Unlabelled: Numerous studies have shown that topical timolol is effective in treating infantile hemangioma (IH) with minimal adverse events. However, consensus is lacking on optimal timing, dosage, frequency, and safety parameters for this treatment. This study aims to explore the timing and safety of topical timolol treatment for superficial IH.
View Article and Find Full Text PDFEfficacy of the 595 nm pulsed dye laser in the treatment of hemangiomas in Vietnamese patients.
Lasers Med Sci
January 2025
Aalborg University Hospital, Aalborg, Denmark.
Hemangiomas are common benign vascular tumors that often present in childhood. The 595 nm pulsed dye laser (PDL) is now being widely used to treat vascular skin lesions. This case series was performed to review the therapeutic efficacy and safety of PDL in the treatment of hemangiomas among Vietnamese patients.
View Article and Find Full Text PDF'PHACE' on the 'face'.
BMJ Case Rep
January 2025
Paediatric Department, SJOG Midland Public Hospital, Midland, Western Australia, Australia.
Infantile haemangiomas are a common presentation in infants within the first few months of life. The majority of haemangiomas are benign; however, large haemangiomas (≥5 cm), especially those involving the face, may indicate a more serious underlying neurocutaneous disorder known as PHACE (Posterior fossa malformations, Haemangioma, Arterial anomalies, Coarctation of the aorta/Cardiac defects and Eye abnormalities) syndrome. The authors report an unusual case of possible PHACE syndrome in a young male toddler with a large facial haemangioma.
View Article and Find Full Text PDFOptimizing Propranolol Therapy for Infantile Hemangiomas: The Role of the Multidisciplinary Team.
Cureus
December 2024
Department of Pediatrics, Toranomon Hospital, Tokyo, JPN.
Background: Oral propranolol therapy is currently the first choice for infants with infantile hemangiomas (IHs) requiring systemic treatment. This study aims to evaluate the safety and effectiveness of oral propranolol therapy for IHs and to assess the role of a multidisciplinary medical team in supporting optimal treatment.
Materials And Methods: Clinical data were retrospectively reviewed from medical records in 150 Japanese infants with IH treated with propranolol orally at Toranomon Hospital.
Neurodevelopmental Effects of Propranolol Treatment During Infancy in Infantile Hemangioma Patients.
Children (Basel)
December 2024
Department of Pediatric Hematology and Oncology, Istanbul Medical Faculty, İstanbul University, 34098 Istanbul, Turkey.
Introduction And Aim: Propranolol is an effective treatment option for infantile hemangiomas, but there is still insufficient information about neurodevelopmental side effects of propranolol. In our study, the neurodevelopmental levels of infantile hemangioma patients receiving propranolol treatment were examined using the Bayley-III test.
Method: In our single-center, cross-sectional study, patients were recruited between 1 January 2020 and 31 December 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!